原发性肺腺癌中Napsin A、TTF1及SPA蛋白的表达及其与EGFR基因突变的相关性

发布时间：2018-03-14 23:33

本文选题：免疫组织化学标志物　切入点：Napsin　出处：《肿瘤防治研究》2017年09期 　论文类型：期刊论文

【摘要】：目的探讨Napsin A、TTF1、SPA在原发性肺腺癌中的表达及与EGFR基因突变的相关性。方法免疫组织化学法检测306例原发性肺腺癌组织中Napsin A、TTF1、SPA蛋白的表达。ARMS法同时检测这些组织中EGFR基因是否突变。结果 Napsin A在原发性肺腺癌中表达率为87.25%,TTF1在原发性肺腺癌中表达率为80.72%,SPA在原发性肺腺癌中表达率为60.46%。EGFR基因在原发性肺腺癌中的突变率为40.20%。TTF1、Napsin A、SPA蛋白表达阳性患者EGFR基因突变率均较表达阴性患者高,差异均有统计学意义(P0.01)。结论我们可以通过检测Napsin A、TTF1和SPA是否表达来简单预测原发性肺腺癌中EGFR基因是否会有突变,这对于一些组织不够用于开展分子检测的患者或不能开展分子检测的医院十分实用。
[Abstract]:Objective to investigate the expression of Napsin TTF1 SPA in primary lung adenocarcinoma and its correlation with EGFR gene mutation. Methods the expression of Napsin Agna TTF1 SPA protein in 306 cases of primary lung adenocarcinoma was detected by immunohistochemical method. ARMS method was used to detect EGFR in these tissues simultaneously. Results the expression rate of Napsin A in primary lung adenocarcinoma was 87.25 and that in primary lung adenocarcinoma was 80.72. The expression rate of Napsin in primary lung adenocarcinoma was 60.46.EGFR gene mutation rate in primary lung adenocarcinoma was 40.20.TTF1 Napsin Aspa protein. The mutation rate of EGFR gene in patients with positive expression was higher than that in patients with negative expression. Conclusion We can simply predict the mutation of EGFR gene in primary lung adenocarcinoma by detecting the expression of Napsin ATTF1 and SPA. This is useful for some tissues that are not used for molecular testing in patients or hospitals where molecular testing is not possible.
【作者单位】：江南大学附属医院(无锡市第四人民医院)病理科;
【基金】：无锡市医管中心科研项目(YGZXM1540)
【分类号】：R734.2

【相似文献】